Cargando…

Inhibitory activities of selected Kampo formulations on human aldose reductase

BACKGROUND: Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kamp...

Descripción completa

Detalles Bibliográficos
Autores principales: Onoda, Toshihisa, Ishikawa, Chikako, Fukazawa, Takahiro, Li, Wei, Obayashi, Masahiko, Koike, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228067/
https://www.ncbi.nlm.nih.gov/pubmed/25374323
http://dx.doi.org/10.1186/1472-6882-14-435
_version_ 1782343907815718912
author Onoda, Toshihisa
Ishikawa, Chikako
Fukazawa, Takahiro
Li, Wei
Obayashi, Masahiko
Koike, Kazuo
author_facet Onoda, Toshihisa
Ishikawa, Chikako
Fukazawa, Takahiro
Li, Wei
Obayashi, Masahiko
Koike, Kazuo
author_sort Onoda, Toshihisa
collection PubMed
description BACKGROUND: Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore the possibilities of novel clinical applications of these formulations in the treatment of diabetes complications. METHODS: The hAR inhibitory activities of four Kampo formulations that are clinically used for diabetic neuropathy, four Kampo formulations that are used for cognitive disorders, and a total of 21 component crude drugs were measured. Furthermore, the hAR inhibitory activity of Glycyrrhizae Radix preparata was measured to determine the effect of frying, which is one of the specific processing of Glycyrrhizae Radix. hAR inhibitory activity was determined by measuring the rate of decline in the absorbance of NAPH at 340 nm using 0.5 mM NADPH, 10 mM D,L-glyceraldehyde, and 3.6 mU/mL hAR in phosphate buffer solution (0.2 M, pH 6.2). RESULTS: All of the Kampo formulations exhibited significant hAR inhibitory activity; Chotosan exhibited particularly strong activity. Among the 21 crude drugs tested, adequate inhibitory activities were found for the following, in descending order of activity: Glycyrrhizae Radix > Paeoniae Radix > Chrysanthemi Flos > Cinnamomi Cortex > Phellodendri Cortex > Uncariae Uncis cum Ramulus > Bupleuri Radix. Glycyrrhizae Radix preparata exhibited an inhibitory activity that was nearly identical to that of Glycyrrhizae Radix. CONCLUSIONS: Despite their seemingly different treatment objectives, all of the Kampo formulations that are clinically used for diabetes complications demonstrated significant hAR inhibitory activity. This activity might underlie the characteristic multi-target effects of Kampo formulations. Although the overall effect of a Kampo formulation is certainly difficult to evaluate based on specific herbal medications or components, the approach as taken in this study might nonetheless contribute to further advancement in the development of new drugs via the review of proper usage and re-examination of the chemical compounds from a new perspective.
format Online
Article
Text
id pubmed-4228067
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42280672014-11-12 Inhibitory activities of selected Kampo formulations on human aldose reductase Onoda, Toshihisa Ishikawa, Chikako Fukazawa, Takahiro Li, Wei Obayashi, Masahiko Koike, Kazuo BMC Complement Altern Med Research Article BACKGROUND: Diabetes complications include various symptoms such as diabetic neuropathy and cognitive disorders. Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway and is one of the causal factors of diabetes complications. In this study, the bioactivities of eight selected Kampo formulations that are currently in clinical use for diabetes complications were assessed using human AR (hAR) inhibitory activity as the primary parameter to explore the possibilities of novel clinical applications of these formulations in the treatment of diabetes complications. METHODS: The hAR inhibitory activities of four Kampo formulations that are clinically used for diabetic neuropathy, four Kampo formulations that are used for cognitive disorders, and a total of 21 component crude drugs were measured. Furthermore, the hAR inhibitory activity of Glycyrrhizae Radix preparata was measured to determine the effect of frying, which is one of the specific processing of Glycyrrhizae Radix. hAR inhibitory activity was determined by measuring the rate of decline in the absorbance of NAPH at 340 nm using 0.5 mM NADPH, 10 mM D,L-glyceraldehyde, and 3.6 mU/mL hAR in phosphate buffer solution (0.2 M, pH 6.2). RESULTS: All of the Kampo formulations exhibited significant hAR inhibitory activity; Chotosan exhibited particularly strong activity. Among the 21 crude drugs tested, adequate inhibitory activities were found for the following, in descending order of activity: Glycyrrhizae Radix > Paeoniae Radix > Chrysanthemi Flos > Cinnamomi Cortex > Phellodendri Cortex > Uncariae Uncis cum Ramulus > Bupleuri Radix. Glycyrrhizae Radix preparata exhibited an inhibitory activity that was nearly identical to that of Glycyrrhizae Radix. CONCLUSIONS: Despite their seemingly different treatment objectives, all of the Kampo formulations that are clinically used for diabetes complications demonstrated significant hAR inhibitory activity. This activity might underlie the characteristic multi-target effects of Kampo formulations. Although the overall effect of a Kampo formulation is certainly difficult to evaluate based on specific herbal medications or components, the approach as taken in this study might nonetheless contribute to further advancement in the development of new drugs via the review of proper usage and re-examination of the chemical compounds from a new perspective. BioMed Central 2014-11-06 /pmc/articles/PMC4228067/ /pubmed/25374323 http://dx.doi.org/10.1186/1472-6882-14-435 Text en © Onoda et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Onoda, Toshihisa
Ishikawa, Chikako
Fukazawa, Takahiro
Li, Wei
Obayashi, Masahiko
Koike, Kazuo
Inhibitory activities of selected Kampo formulations on human aldose reductase
title Inhibitory activities of selected Kampo formulations on human aldose reductase
title_full Inhibitory activities of selected Kampo formulations on human aldose reductase
title_fullStr Inhibitory activities of selected Kampo formulations on human aldose reductase
title_full_unstemmed Inhibitory activities of selected Kampo formulations on human aldose reductase
title_short Inhibitory activities of selected Kampo formulations on human aldose reductase
title_sort inhibitory activities of selected kampo formulations on human aldose reductase
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228067/
https://www.ncbi.nlm.nih.gov/pubmed/25374323
http://dx.doi.org/10.1186/1472-6882-14-435
work_keys_str_mv AT onodatoshihisa inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase
AT ishikawachikako inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase
AT fukazawatakahiro inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase
AT liwei inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase
AT obayashimasahiko inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase
AT koikekazuo inhibitoryactivitiesofselectedkampoformulationsonhumanaldosereductase